Drug intelligence / Profile preview

AVI-103

Development stage: Preclinical
Lead developer: AbVision
Modality: Monoclonal Antibodies → Antibody-Based Therapeutics

Overview

AVI-103 is a preclinical **monoclonal antibody** developed by **AbVision** for **cancer**. It is designed to bind and block **cytotoxic T-lymphocyte-associated protein 4**, an immune checkpoint receptor that suppresses T-cell activation, with the goal of enhancing anti-tumor immune responses. Based on the company pipeline information, AVI-103 is an anti-CTLA-4 immuno-oncology program and has been described as available for out-licensing.

Other names: Anti-CTLA-4Anti-CTLA4Anti-CTLA 4

Targets

CTLA-4 (Cytotoxic t-lymphocyte–associated protein 4)

Beyond the preview

Go deeper on AVI-103.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on AVI-103.

Explore the full profile